These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 19278811

  • 1. Urinary TGF-beta1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases.
    Park HC, Choi HY, Kim BS, An HR, Lee JS, Ha SK, Han DS.
    Biomed Pharmacother; 2009 Nov; 63(9):672-8. PubMed ID: 19278811
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R, Siva S, Dunn SR, Sharma K.
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [Abstract] [Full Text] [Related]

  • 4. Antiproteinuric effect of losartan in non-diabetic renal disease is not dependent on ACE insertion/deletion polymorphism.
    Park HC, Choi HY, Kim BS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS.
    Kidney Blood Press Res; 2006 Mar; 29(4):216-24. PubMed ID: 16960460
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.
    Horita Y, Taura K, Taguchi T, Furusu A, Kohno S.
    Nephrology (Carlton); 2006 Oct; 11(5):462-6. PubMed ID: 17014562
    [Abstract] [Full Text] [Related]

  • 14. [Pharmacogenetics of angiotensin system in non diabetic nephropathy].
    Coto E, Marín R, Alvarez V, Praga M, Fernández Andrade C, Arias M, Poveda R, Vallés M, Galcerán JM, Luño J, Rivera F, Campistol JM.
    Nefrologia; 2005 Oct; 25(4):381-6. PubMed ID: 16231503
    [Abstract] [Full Text] [Related]

  • 15. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
    Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE.
    J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of losartan on proteinuria and urinary angiotensinogen excretion in non-diabetic patients with chronic kidney disease.
    Lee YJ, Cho S, Kim SR, Jang HR, Lee JE, Huh W, Kim DJ, Oh HY, Kim YG.
    Postgrad Med J; 2011 Oct; 87(1032):664-9. PubMed ID: 21715572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.